Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent belonging to a class of drugs known as taxanes, which are widely used in the treatment of cancer. In December 2017, Odonate initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
View Top Employees from Odonate Therapeutics™Website | https://www.odonate.com/ |
Ticker | ODT |
Revenue | $28.2 million |
Employees | 32 (28 on RocketReach) |
Founded | 2013 |
Address | 3 E 28th St Fl 10, New York, New York 10016, US |
Phone | (332) 206-0935 |
Technologies |
JavaScript,
HTML,
Twitter
+14 more
(view full list)
|
Industry | Biotechnology, Business Services General, Oncology, Pharmaceuticals, Business Services, Science and Engineering, Drug Development, Clinical |
Competitors | Enzon Pharmaceuticals, HARBOUR BIOMED, Otonomy, Inc, Puma Biotechnology, Inc., Verastem Oncology |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Odonate Therapeutics™ employee's phone or email?
The Odonate Therapeutics™ annual revenue was $28.2 million in 2023.
Robert Rosen is the Board Member of Odonate Therapeutics™.
28 people are employed at Odonate Therapeutics™.
Odonate Therapeutics™ is based in New York, New York.
The NAICS codes for Odonate Therapeutics™ are [325, 3254, 32541, 32].
The SIC codes for Odonate Therapeutics™ are [28, 283].